Biberach an der Riss
Germany
83
2026-04-09
The entities that hold a legal rights for patent applications filed by inventor Mark Michael:
Michael Mark from Biberach an der Riss, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#2 | 2025-03-13TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG
#3 | 2025-02-27USES OF DPP IV INHIBITORS
#4 | 2024-10-10PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#5 | 2024-09-12USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#6 | 2024-05-16VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY
#7 | 2024-05-09TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUG
#8 | 2023-09-14Pharmaceutical composition, methods for treating and uses thereof
#9 | 2022-10-27Use of a DPP-4 inhibitor in SIRS and/or sepsis
#10 | 2022-10-06PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#11 | 2022-06-16Uses of DPP IV inhibitors
#12 | 2022-05-19PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#13 | 2021-12-09USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#14 | 2021-11-11PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#15 | 2021-09-16PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#16 | 2021-07-15COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF
#17 | 2021-06-03Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
#18 | 2021-04-29Vasoprotective and cardioprotective antidiabetic therapy
#19 | 2021-04-22PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#20 | 2020-12-24PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#21 | 2020-07-16Uses of DPP IV inhibitors
#22 | 2020-05-21TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUG
#23 | 2020-03-19PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#24 | 2020-03-05PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#25 | 2020-02-13TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
#26 | 2019-07-04USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
#27 | 2019-04-04USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#28 | 2019-01-03TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
#29 | 2018-12-13Uses of DPP IV inhibitors
#30 | 2018-07-12PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#31 | 2018-04-19Pharmaceutical Composition, Methods for Treating and Uses Thereof
#32 | 2017-12-28TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG
#33 | 2017-11-30VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY
#34 | 2017-10-26PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#35 | 2017-06-01Combination therapy
#36 | 2017-03-30Uses of DPP IV inhibitors
#37 | 2017-03-238-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#38 | 2017-03-09Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
#39 | 2017-01-26PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#40 | 2016-12-08Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
#41 | 2016-12-011-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL
#42 | 2016-07-21PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES
#43 | 2016-07-078-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
#44 | 2016-06-09PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#45 | 2016-05-19PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES
#46 | 2016-03-24Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
#47 | 2016-03-03TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG
#48 | 2016-02-11Combination therapy
#49 | 2016-01-07USES OF DPP IV INHIBITORS
#50 | 2015-10-158-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#51 | 2015-07-16VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY
#52 | 2014-11-20COMBINATION OF A CERTAIN DPP-4 INHIBITOR AND VOGLIBOSE
#53 | 2014-09-11PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#54 | 2014-08-141-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-AXANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL
#55 | 2014-05-15Uses of DPP IV inhibitors
#56 | 2014-05-088-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#57 | 2014-03-27PHARMACEUTICAL COMPOSITION COMPRISING AN SGLT2 INHIBITOR AND A PPAR- GAMMA AGONIST AND USES THEREOF
#58 | 2014-03-27PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#59 | 2014-02-27XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#60 | 2014-02-06Pharmaceutical composition, methods for treating and uses thereof
#61 | 2014-01-30PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#62 | 2013-12-05Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
#63 | 2013-11-28USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR
#64 | 2013-11-21Combination therapy for the treatment of diabetes and related conditions
#65 | 2013-11-14USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
#66 | 2013-11-14USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
#67 | 2013-10-24Combination therapy
#68 | 2013-08-01Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
#69 | 2013-07-04SUBCUTANEOUS THERAPEUTIC USE OF DPP-4 INHIBITOR
#70 | 2013-06-27XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
#71 | 2013-05-02Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
#72 | 2013-03-14INDUCIBLE EXPRESSION OF SGLT5, METHODS AND KITS USING THE SAME
#73 | 2013-02-07PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#74 | 2012-11-08PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#75 | 2012-10-04Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#76 | 2012-10-04Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
#77 | 2012-08-168-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
#78 | 2012-08-02PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#79 | 2012-06-28Diabetes therapy
#80 | 2012-05-17Vasoprotective and cardioprotective antidiabetic therapy
#81 | 2012-02-16Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
#82 | 2012-02-09Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
#83 | 2011-09-291-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL
79784 ⎘